ENT-1402

N/A

Report date: 2023/03/03 13:59:51
NME

Base Information

Drug NameENT-1402
Drug Alias NameENT-1402
ClassificationSmall molecules > Proteolysis-Targeting Chimera (PROTAC)
Mechanisms of ActionAnaplastic lymphoma kinase degraders
TargetsAnaplastic lymphoma kinase
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungLymphoma, Large-Cell, Anaplastic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesEndotarget
China Registration ClassN/A

Develop Information

Active CompaniesEndotarget
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell LungLymphoma, Large-Cell, Anaplastic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A